Personal Statement of Mayke Oosterloo

…Currently, I am involved in clinical and scientific research both nationally and internationally regarding HD. I believe I could make a contribution to the tasks of the Executive Committee (EC)… […]

Weiterlesen…

Ethical and Legal Considerations

…ongoing three years after the Regulation has come into operation. Further information, including on the expected application date for the Regulation, is available from the European Medicines Agency: www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trial-regulation…. […]

Weiterlesen…

Cognitive Phenotype WG

reliable and sufficiently specific? How do structural and functional brain changes translate into the cognitive decline observed in HD? How do cognitive impairments impact functional independence? Can we measure functional… […]

Weiterlesen…

Extract2_07/2023_NL-Issue49

…key to fostering solutions. I also work with pharmaceutical companies and people in industry to share perspectives about the latest research news and help bridge the gap between pharmaceutical companies,… […]

Weiterlesen…

EHDN 2024

…to clinicians, scientists, HD advocacy delegates, and members of families affected by HD. Latest Program Version: PDF download Reimbursement (Reimbursement forms need to be submitted no later then 30th November)… […]

Weiterlesen…

About Us

…Foundation – www.chdifoundation.org For the rest, please read the imprint of the Universitätsklinikum Ulm. Pictures Shutterstock images are used under license from Shutterstock.com. EHDN would like to thank Shutterstock…. […]

Weiterlesen…

Systems Modelling WG

…Aims There are two main ways to study HD, and they are highly complementary. One is to study disease mechanisms using experimental biology. The other is to take a… […]

Weiterlesen…

extract1_04/2023_NL-issue48

…of protein misfolding in HD and using model systems to do this. This was probably in 2003 and I was immediately excited – as a trained geneticist, I saw this… […]

Weiterlesen…